Algert Global LLC raised its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 192.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 259,160 shares of the biopharmaceutical company's stock after buying an additional 170,575 shares during the period. Algert Global LLC owned about 0.09% of Amicus Therapeutics worth $2,768,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the business. OLD Second National Bank of Aurora bought a new position in Amicus Therapeutics in the 3rd quarter valued at about $26,000. Hazlett Burt & Watson Inc. boosted its stake in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 1,569 shares during the period. Blue Trust Inc. grew its holdings in Amicus Therapeutics by 1,705.4% in the 3rd quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI bought a new position in Amicus Therapeutics during the 3rd quarter worth $32,000. Finally, Headlands Technologies LLC acquired a new position in shares of Amicus Therapeutics in the second quarter valued at about $89,000.
Insider Activity
In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company's stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the sale, the chief executive officer now owns 886,654 shares of the company's stock, valued at approximately $9,398,532.40. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders sold 30,401 shares of company stock valued at $352,038. Company insiders own 2.20% of the company's stock.
Amicus Therapeutics Trading Up 0.9 %
NASDAQ FOLD traded up $0.09 on Wednesday, hitting $9.96. The company's stock had a trading volume of 1,193,229 shares, compared to its average volume of 2,702,495. The firm has a market cap of $2.98 billion, a PE ratio of -29.03 and a beta of 0.68. The company's 50-day moving average is $10.77 and its 200 day moving average is $10.59. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. Amicus Therapeutics, Inc. has a 1-year low of $9.02 and a 1-year high of $14.57.
Analysts Set New Price Targets
A number of research analysts have issued reports on FOLD shares. Guggenheim increased their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. raised their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 12th. StockNews.com upgraded Amicus Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, November 16th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald upped their price target on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $17.63.
Check Out Our Latest Report on Amicus Therapeutics
Amicus Therapeutics Profile
(
Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Featured Articles
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
